DickSIM
Prima o poi....ci becco!
magari stanno facendo un pacco regalo......... 
statine e Naprox per cash e future royalties......
eccccchillosaaaaaaaaaa??? 
NicOx.... in attesa di.....
- Creatore Discussione DickSIM
- Data di Inizio
magari stanno facendo un pacco regalo......... statine e Naprox per cash e future royalties...... eccccchillosaaaaaaaaaa???
DickSIM
Prima o poi....ci becco!
doc....calendario ricco! 
Nicox is planning to attend the following events during the first semester 2013:
Financial and Business conferences
31st Annual J.P. Morgan Healthcare Conference January 7-1 San Francisco, USA BIO CEO & Investor conference February 11-12 New York, USA BIO International Convention April 22-25 Chicago, USA
Scientific conferences
Hawaiian Eye meeting - Booth Nicox: 208
January 20-25 Hawaii ACES/SEE Caribbean Eye
February 8-12 San Juan, Puerto Rico SECO, South Eastern Congress of Optometry International - Booth Nicox: 241 February 27-March 3 Atlanta, USA American Glaucoma Society February 28-March 3 San Francisco, USA ISOPT Clinical
International Symposium on Ocular Pharmacology and therapeutics March 7-10 Paris, France AAPOS
American Assosciation for Pediatric Ophthalmology and Strabismus - Booth Nicox: 3 April 3-7 Boston, USA ASCRS
American Society of Cataract and Refractive Surgery April 20-24 San Francisco, USA ARVO
Association for Research in Vision and Ophthalmology May 5-9 Seattle, USA SFO, Société Française d'Ophthalmologie - Booth Nicox: N12 May 1-14 Paris, France SOI International Congress May 15-18 Milano, Italy Royal College of Ophthalmologists Annual congress May 21-23 London, UK SOE - European Congress of Ophthalmology - Booth Nicox: 59B June 8-11 Copenhagen , Danemark AOA - Optometry's meeting - Booth Nicox: 1707 June 26-30 San Diego, USA
Nicox is planning to attend the following events during the first semester 2013:
Financial and Business conferences
31st Annual J.P. Morgan Healthcare Conference January 7-1 San Francisco, USA BIO CEO & Investor conference February 11-12 New York, USA BIO International Convention April 22-25 Chicago, USA
Scientific conferences
Hawaiian Eye meeting - Booth Nicox: 208
January 20-25 Hawaii ACES/SEE Caribbean Eye
February 8-12 San Juan, Puerto Rico SECO, South Eastern Congress of Optometry International - Booth Nicox: 241 February 27-March 3 Atlanta, USA American Glaucoma Society February 28-March 3 San Francisco, USA ISOPT Clinical
International Symposium on Ocular Pharmacology and therapeutics March 7-10 Paris, France AAPOS
American Assosciation for Pediatric Ophthalmology and Strabismus - Booth Nicox: 3 April 3-7 Boston, USA ASCRS
American Society of Cataract and Refractive Surgery April 20-24 San Francisco, USA ARVO
Association for Research in Vision and Ophthalmology May 5-9 Seattle, USA SFO, Société Française d'Ophthalmologie - Booth Nicox: N12 May 1-14 Paris, France SOI International Congress May 15-18 Milano, Italy Royal College of Ophthalmologists Annual congress May 21-23 London, UK SOE - European Congress of Ophthalmology - Booth Nicox: 59B June 8-11 Copenhagen , Danemark AOA - Optometry's meeting - Booth Nicox: 1707 June 26-30 San Diego, USA
che succede d_op(a)_ o???????????? 
guly
Forumer storico
neanche un centesimoi su un cesso del genere.vedi keryx,quella si.io ne ho sempre parlato bene e sono stato ricompensato.pero' ricordi quel tua amico cameriere?diceva che non valeva nicox mentre io dicevo che aveva un ottima pipeline e un ottimo ceo.ed oggi abbiamo la proiva.nicox quando mai lo fa un rialzo del genere?preverisco godermi keryx e un altro titolo a cui credo molto (dopo SPPI) e si tratta di RIGEL,quello si he e' ottimo e preferisco investire su ceo molto piu' competenti e credibili non certo su un pallonaro del genere.sposatelo tu se ti piace.A PROPOSITO RIFERISCILO AL TUO AMICO,FORSE ORMAI GLI RESTA DA SERVIRE LE PIZZE A TAVOLA PER COME E' RIDOTTO.NON NE AZZECCA UNA.
guly
Forumer storico
+niente.c'era da aspettarselo.una ottima pipeline.un ottimo management e eu ottimo ceo.mica stiamo parlando di nicox che dopo 10 anni cambia strada.gente seria e capace sopratutto non illusionisti.avete visto cosa sta succedendo? Kerx + 70%
viralic
Forumer storico
magolibero
..se la sà gira..
OK..
va bene..
ma mi pare che ora della fine si parli sempre di quei due trial qui sotto
il comunicato comunque non definisce milestone/step "definiti/individuabili" per quando&come arrivare a corrispondere gli eventuali 165m $
..ma mi son perso io qualcosa nel mese scorso ?
..o queste fasi 3 del NOLatanoprost+Timolo sono passate "inosservate" (partono fra poco)
Search of: BOL‑303259‑X timolol | Phase 3 - List Results - ClinicalTrials.gov
viralic
Forumer storico
Qui si parla di soldi......ora nulla, dopo tanti se approvato
In March 2010, Bausch + Lomb signed a worldwide licensing agreement with Nicox for latanoprostene bunod, and made an initial license payment of $10 million. In light of the positive results of the Phase 2b study completed in 2011, Bausch + Lomb made an additional $10 million milestone payment in April 2012 following their decision to pursue further development of latanoprostene bunod. If certain regulatory, commercialization and sales milestones for latanoprostene bunod are met, Nicox stands to receive from Bausch + Lomb additional potential payments which, over time, could total $162.5 million. Nicox will also receive tiered double-digit royalties on the sales of latanoprostene bunod and has the option to co-promote the product in the United States.
In March 2010, Bausch + Lomb signed a worldwide licensing agreement with Nicox for latanoprostene bunod, and made an initial license payment of $10 million. In light of the positive results of the Phase 2b study completed in 2011, Bausch + Lomb made an additional $10 million milestone payment in April 2012 following their decision to pursue further development of latanoprostene bunod. If certain regulatory, commercialization and sales milestones for latanoprostene bunod are met, Nicox stands to receive from Bausch + Lomb additional potential payments which, over time, could total $162.5 million. Nicox will also receive tiered double-digit royalties on the sales of latanoprostene bunod and has the option to co-promote the product in the United States.
Ultima modifica:
